Pediatric Hodgkin Lymphoma

[1]  P. Nathan,et al.  Risk of solid subsequent malignant neoplasms after childhood Hodgkin lymphoma—Identification of high‐risk populations to guide surveillance: A report from the Late Effects Study Group , 2019, Cancer.

[2]  K. Kelly,et al.  Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma , 2018, Blood.

[3]  Stephen X. Zhang,et al.  Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. , 2018, The Lancet. Haematology.

[4]  L. Constine,et al.  Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group , 2018, Cancer.

[5]  R. Advani,et al.  Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. , 2018, Blood.

[6]  H. Eich,et al.  The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. , 2018, International journal of radiation oncology, biology, physics.

[7]  J. Connors,et al.  Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma , 2017, The New England journal of medicine.

[8]  A. Zelenetz,et al.  Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. , 2017, Blood.

[9]  K. Kelly,et al.  Predictive Factor Analysis of Response-Adapted Radiation Therapy for Chemotherapy-Sensitive Pediatric Hodgkin Lymphoma: Analysis of the Children's Oncology Group AHOD 0031 Trial. , 2016, International journal of radiation oncology, biology, physics.

[10]  M. Shipp,et al.  Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  K. Kelly,et al.  Pediatric Hodgkin Lymphoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  L. Constine,et al.  Implementation of contemporary radiation therapy planning concepts for pediatric Hodgkin lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. , 2015, Practical radiation oncology.

[13]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[14]  Allen R. Chen,et al.  Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Eich,et al.  Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). , 2014, International journal of radiation oncology, biology, physics.

[16]  R. Advani,et al.  ACR appropriateness Criteria® pediatric Hodgkin lymphoma , 2014, Pediatric blood & cancer.

[17]  L. Constine,et al.  Treatment of Pediatric Lymphocyte Predominant Hodgkin Lymphoma (LPHL): A Report from the Children's Oncology Group , 2014 .

[18]  Y. Natkunam,et al.  Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  K. Kelly,et al.  Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma , 2013, Pediatric blood & cancer.

[20]  R. Pötter,et al.  Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Zuofeng Li,et al.  Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. , 2012, International journal of radiation oncology, biology, physics.

[22]  T. Leblanc,et al.  Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Société Française de Lutte contre le Cancer des Enfants et des Adolescents (SFCE) , 2012, British journal of haematology.

[23]  D. Hasenclever,et al.  Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an Anglo-French collaborative report. , 2012, European journal of cancer.

[24]  M. Hudson,et al.  Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. , 2012, JAMA.

[25]  Scott E Smith,et al.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  K. Kelly,et al.  Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma--a report from the Children's Oncology Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  L. Constine,et al.  Treatment of pediatric stage IA lymphocyte-predominant Hodgkin lymphoma with surgical resection alone: A report from the Children's Oncology Group. , 2012 .

[28]  A. Zelenetz,et al.  Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. , 2012, Blood.

[29]  L. Constine,et al.  A Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low Risk Hodgkin Lymphoma (HL) , 2010 .

[30]  W. Klapper,et al.  Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Rahal,et al.  High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma , 2010, Bone Marrow Transplantation.

[32]  B. Coiffier,et al.  Nodular, lymphocyte‐predominant Hodgkin lymphoma , 2010, Cancer.

[33]  C. S. Turner,et al.  A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. , 2009, Blood.

[34]  N. Schmitz,et al.  Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. , 2009, Blood.

[35]  K. Kelly,et al.  Adolescent non‐Hodgkin lymphoma and Hodgkin lymphoma: state of the science , 2009, British journal of haematology.

[36]  N. Schmitz,et al.  Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma , 2008, Bone Marrow Transplantation.

[37]  A. Ng,et al.  Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. , 2008, International journal of radiation oncology, biology, physics.

[38]  Allen R. Chen,et al.  Clinical Outcomes of Patients with Recurrent/Refractory Hodgkin Disease Receiving Cyclosporine, Interferon-γ, and Interleukin-2 Immunotherapy To Induce Autoreactivity after Autologous Stem Cell Transplantation with BEAM: A COG Study. , 2007 .

[39]  C. R. Pinkerton,et al.  Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma – a Children's Cancer and Leukaemia Group report , 2007, British journal of haematology.

[40]  D. Hasenclever,et al.  Resection alone in 58 children with limited stage, lymphocyte‐predominant Hodgkin lymphoma–experience from the European network group on pediatric Hodgkin lymphoma , 2007, Cancer.

[41]  M. Hudson,et al.  Pediatric hodgkin lymphoma: maximizing efficacy and minimizing toxicity. , 2007, Seminars in radiation oncology.

[42]  F. Behm,et al.  POG 8625: A Randomized Trial Comparing Chemotherapy With Chemoradiotherapy for Children and Adolescents With Stages I, IIA, IIIA1 Hodgkin Disease: A Report from the Children's Oncology Group , 2006, Journal of pediatric hematology/oncology.

[43]  E. Noordijk,et al.  Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[44]  J. Connors,et al.  Hodgkin's lymphoma in adolescents. , 2006, Journal of Clinical Oncology.

[45]  R. Pötter,et al.  Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  A. Nademanee,et al.  Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. , 2005, Blood.

[47]  T. Merchant,et al.  Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  M. Amylon,et al.  High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  C. R. Pinkerton,et al.  Outcome After Autologous Hemopoietic Stem Cell Transplantation in Relapsed or Refractory Childhood Hodgkin Disease , 2004, Journal of pediatric hematology/oncology.

[50]  S. Lipsitz,et al.  Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  T. Merchant,et al.  Differential attenuation of clavicle growth after asymmetric mantle radiotherapy. , 2004, International journal of radiation oncology, biology, physics.

[52]  R. Pötter,et al.  The Concept of the GPOH-HD 2003 Therapy Study for Pediatric Hodgkin's Disease: Evolution in the Tradition of the DAL/GPOH Studies , 2004, Klinische Padiatrie.

[53]  H. van den Berg,et al.  Decreasing the number of MOPP courses reduces gonadal damage in survivors of childhood hodgkin disease , 2004, Pediatric blood & cancer.

[54]  H. Katzenstein,et al.  Results of Little or No Treatment for Lymphocyte-Predominant Hodgkin Disease in Children and Adolescents , 2003, Journal of pediatric hematology/oncology.

[55]  G. Leverger,et al.  Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection--a Study of the French Society of Pediatric Oncology. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  V. Diehl,et al.  Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. , 2003, The New England journal of medicine.

[57]  R. Pötter,et al.  Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. , 2003, Klinische Padiatrie.

[58]  J. Imeson,et al.  ChlVPP chemotherapy in children with stage IV Hodgkin's disease: results of the UKCCSG HD 8201 and HD 9201 studies , 2002, British journal of haematology.

[59]  P. Davis,et al.  Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  K. Lamborn,et al.  VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  M. Hudson,et al.  Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  M. Hudson,et al.  Lymphocyte-Predominant Hodgkin Disease in Children , 2002, Journal of pediatric hematology/oncology.

[63]  S. Perkins,et al.  Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  K. Dieckmann,et al.  Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 trial. , 2001, International journal of radiation oncology, biology, physics.

[65]  H. Storm,et al.  Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  G. Leverger,et al.  Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  D. Green,et al.  Second malignant neoplasms after treatment for Hodgkin's disease in childhood or adolescence. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  D. Green,et al.  Cancer and cardiac mortality among 15-year survivors of cancer diagnosed during childhood or adolescence. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  J. Armitage,et al.  Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  V. Diehl,et al.  Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  M. Hudson,et al.  Increased mortality after successful treatment for Hodgkin's disease. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  K. Lamborn,et al.  Second cancers following pediatric Hodgkin's disease. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  C. R. Pinkerton,et al.  Does histology influence outcome in childhood Hodgkin's disease? Results from the United Kingdom Children's Cancer Study Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  S. Shalet,et al.  Gonadal function following chemotherapy for childhood Hodgkin's disease. , 1996, Medical and pediatric oncology.

[75]  A Kreuger,et al.  Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  L. Robison,et al.  Breast cancer and other second neoplasms after childhood Hodgkin's disease. , 1996, The New England journal of medicine.

[77]  W. Chan,et al.  Clonal relationship between lymphocytic predominance Hodgkin's disease and concurrent or subsequent large-cell lymphoma of B lineage. , 1995, Blood.

[78]  D. Fairclough,et al.  Serial pulmonary function studies in children treated for newly diagnosed Hodgkin's disease with mantle radiotherapy plus cycles of cyclophosphamide, vincristine, and procarbazine alternating with cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine , 1995, Cancer.

[79]  S. Donaldson,et al.  ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience. , 1994, Journal of Clinical Oncology.

[80]  R. Warnke,et al.  Nodular lymphocyte predominance Hodgkin's disease. A distinct clinicopathological entity. , 1994, The American journal of surgical pathology.

[81]  J. Armitage,et al.  Autologous bone marrow transplantation for pediatric Hodgkin's disease: a case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  S. Pileri,et al.  Treatment of pediatric hodgkin disease tailored to stage, mediastinal mass, and age an italian (aieop) multicenter study on 215 patients , 1993 .

[83]  S. Hancock,et al.  Cardiac disease following treatment of Hodgkin's disease in children and adolescents. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  K. Propert,et al.  Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. , 1992, The New England journal of medicine.

[85]  G. Leverger,et al.  Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  F. Behm,et al.  Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  E. Nieschlag,et al.  The effects of different cumulative doses of chemotherapy on testicular function. Results in 75 patients treated for Hodgkin's disease during childhood or adolescence , 1990, Cancer.

[88]  N. Day,et al.  Leukemia following Hodgkin's disease. , 1990, The New England journal of medicine.

[89]  C. Haanen,et al.  Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  S. Donaldson,et al.  Pediatric Hodgkin's disease: pulmonary, cardiac, and thyroid function following combined modality therapy. , 1989, International journal of radiation oncology, biology, physics.

[91]  J. Brämswig,et al.  Zur Bedeutung des Procarbazins in der Chemotherapie des Morbus Hodgkin - Ein Bericht der kooperativen Therapiestudie DAL-HD-85* , 1988 .

[92]  J. Cassady,et al.  An evaluation of long‐term survival and treatment complications in children with Hodgkin's disease , 1983, Cancer.

[93]  S. Rosenberg,et al.  A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  A. Santoro,et al.  ABVD chemotherapy in the treatment of Hodgkin's disease. , 1982, Cancer treatment reviews.

[95]  S. Donaldson,et al.  Thyroid dysfunction after radiotherapy in children with Hodgkin's disease , 1980, Cancer.

[96]  S. Donaldson,et al.  Pediatric Hodgkin's disease. II. Results of therapy , 1976, Cancer.

[97]  H. Kaplan,et al.  Growth retardation in children after megavoltage irradiation of the spine , 1973, Cancer.

[98]  P. Rubin,et al.  Cancer genesis across the age spectrum: associations with tissue development, maintenance, and senescence. , 2010, Seminars in radiation oncology.

[99]  R. Tsang,et al.  Hodgkin lymphoma across the age spectrum: epidemiology, therapy, and late effects. , 2010, Seminars in radiation oncology.

[100]  M. Cairo,et al.  Stem cell transplantation for pediatric lymphoma: past, present and future , 2008, Bone Marrow Transplantation.

[101]  A. Horwich,et al.  Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[102]  Steven E Lipshultz,et al.  Radiation-associated cardiovascular disease. , 2003, Critical reviews in oncology/hematology.

[103]  M. Amylon,et al.  High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin's disease: atopy predicts idiopathic diffuse lung injury syndromes. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[104]  G. Schellong.  Treatment of children and adolescents with Hodgkin's disease: the experience of the German-Austrian Paediatric Study Group. , 1996, Bailliere's clinical haematology.

[105]  S. Donaldson,et al.  Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: the Stanford experience. , 1990, International journal of radiation oncology, biology, physics.

[106]  D. Green,et al.  Pregnancy outcome following treatment during childhood or adolescence for Hodgkin's disease. , 1988, Pediatric hematology and oncology.